Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope

Executive Summary

A portfolio review concluded that 'the next step to unlock shareholder value is … exploring strategic alternatives for that Tysabri royalty stream,' CEO John Hendrickson said during Perrigo's third-quarter earnings briefing.

Advertisement

Related Content

Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
Perrigo Changes Reporting Structure In Latest Stop On Cost-Cutting Trail
Perrigo Wants Answers From Former Owner Of Its Branded Consumer Business
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor
Perrigo CEO defends Elan acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel